Patently-O

SEPTEMBER 26, 2022

Topics: Enablement / Written Description (All three are biotech / pharma): 3 Cases; Infringement (FDA Labeling): 1 Case; Anticipation (On Sale Bar): 1 Case; Double Patenting (Still the law?) by Dennis Crouch. It is time to pick-up our consideration of Supreme Court patent cases for the 2022-2023 term.

Patent Law 125

Patent Law Law Patent Invention 125

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 7, 2022

With the PTAB’s constitutional defect now cured, the post-grant world refocused its attention back to more typical matters – discretionary denial, institution reviewability, and the one-year time bar, among other issues. Discretionary Denials Update: A New Tool for Overcoming Fintiv ? Download a PDF. Table of Contents.

Reporting 52

Reporting Art Invention Patent 52

Fish & Richardson Trademark & Copyright Thoughts

APRIL 1, 2022

The director’s de novo review yields no deference to the board’s decision, a notable distinction from the rehearing procedure, which is limited to issues “the Board misapprehended or overlooked.”[5]. Read the full article on Law360. PDF copy available. On June 21, 2021, the U.S. Arthrex Inc. Arthrex Inc. Constitution.[2].

Patent 52

Patent Art Technology Law 52

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 11, 2022

Introduction. 2021 saw several important milestones in the biosimilars space, including the much anticipated first interchangeable designations by FDA and the approval of the first ophthalmology biosimilar. The biosimilar market also exhibited continued growth, with multiple biosimilar developers reporting strong sales of biosimilars through 2021.

Litigation 52

Litigation Settlement Patent Marketing 52